Hijazi Abu Ali | Birzeit University (original) (raw)
Papers by Hijazi Abu Ali
Cheminform, 2010
ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance t... more ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Studies in Inorganic Chemistry, 2006
Journal of Coordination Chemistry, 2016
Studies in Inorganic Chemistry, 2006
ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high li... more ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high linear energy transfer of α-particles and recoiling 7Li nuclei. Neither the boron nor the neutrons each alone can cause tissue damage; however, the neutron absorption by the boron provides the high energy to be effective in the biological compartment. For this binary system (BNCT) to be successful, not only high energy neutron beams have to be employed, but also high tumor concentrations of 10B and high tumor: normal tissue ratio must be achieved. BNCT was initially implemented in brain tumors and melanomas; however it seems that it will be gradually expanded to other types of cancer in future. Several boronic entities have been used clinically with limited successful results; however, more entities are being investigated in laboratories with promising potentials. Today, only few clinical trials on BNCT have been conducted around the world, one major reason for its limited use can be attributed to the neutron source, which is a nuclear reactor and its high costs. If the clinical results would justify the costs, BNCT may have the opportunity to become a daily procedure in hospital all over the world. However, the results from the clinical trial of BNCT are not groundbreaking, and that is attributed, as in other cancer therapies, to the lack of sufficient differentiation between tumor and normal cells. The research in the future should be focused on studying and developing new boron entities with such biochemical and physicochemical properties to achieve tumor targeting in vivo, and to bring it to the clinical use.
Studies in Inorganic Chemistry, 2006
This chapter discusses the chemistry of the diboron compounds. Diborane reagents of the general f... more This chapter discusses the chemistry of the diboron compounds. Diborane reagents of the general formula B2(OR)4 have been utilized recently as reagents for a series of transition metal-catalyzed reactions. Synthesis of diboron compounds may involve either reductive coupling reactions of monoboron derivatives to form the boron-boron bond, or reactions of compounds possessing preformed B2 fragments. Two aspects of the boron chemistry of this class of compounds are particularly relevant: (1) First, synthesis and properties of organodiboron derivatives and authentic synthetic failure in this area are of interest in comparison with the rich organic chemistry of monoboron derivatives. (2) Second, the chemistry of subvalent boron compounds and their interactions with organic and organometallic systems can lead to novel reactions that make organoboron derivatives accessible. Bisdiborane derivatives are an important class of compounds in boron chemistry. The addition of diboranes (X2B–BX2) to unsaturated hydrocarbons is an attractive and straightforward method to introduce two boryl units into organic molecules. Diborane itself, B2H4, is stable only when complexed by Lewis base ligands such as amines or phosphines.
ChemInform, 2006
... Similarly, (R)-(-)5,6-dihydro-6-pentyl-2H-pyran-2-one (massoia lactone, 41), isolated from ba... more ... Similarly, (R)-(-)5,6-dihydro-6-pentyl-2H-pyran-2-one (massoia lactone, 41), isolated from bark oil of Criptocarya massoia [42] and jasmine flowers [43] is also found in the defense secretion ... [29] R. Pereda-Miranda, L. Hem~indez, MJ Villavicencio, M. Novelo, P. Ibarra, H. Chai ...
ChemInform, 2007
refs.]. -(DEMBITSKY, V. M.; ABU ALI, H.; SREBNIK, M.; Stud. Inorg. Chem. 22 (2005) 367-389; Dep. ... more refs.]. -(DEMBITSKY, V. M.; ABU ALI, H.; SREBNIK, M.; Stud. Inorg. Chem. 22 (2005) 367-389; Dep. Med. Chem., Sch. Pharm., Hebrew Univ., Jerusalem 91120, Israel; Eng.) -Lindner 26-247
Acta Crystallogr C Cryst Str, 2001
Journal of Organometallic Chemistry, Oct 1, 2009
The dinuclear complex tetra(μ-valproato) dirhodium(II), Rh2(valp)4 (1), and its bis-adducts with ... more The dinuclear complex tetra(μ-valproato) dirhodium(II), Rh2(valp)4 (1), and its bis-adducts with theophylline, Rh2(valp)4(ThH)2 (4), or caffeine, Rh2(valp)4(Caf)2 (5), have been synthesized and characterized by elemental analysis, IR, UV–Vis, magnetic moment, 1H and 13C NMR spectroscopic techniques. Spectral data for the complexes are consistent with a dinuclear structure as found for rhodium (II) tetracarboxylate adducts. Theophylline and caffeine bases in complexes 4 and 5, respectively, are axially coordinated to rhodium (II) atoms through the sterically hindered N(9) site. This is confirmed by X-ray crystal structure analyses of complexes 4 and 5.The dinuclear complex tetra(μ-valproato) dirhodium(II), Rh2(valp)4 (1), and its bis-adducts with theophylline, Rh2(valp)4(ThH)2 (4), or caffeine, Rh2(valp)4(Caf)2 (5), have been synthesized and characterized by various techniques. Within, the syntheses and X-ray structures are reported.
Studies in Inorganic Chemistry, 2006
Organometallics, 2001
Boronic acids have a variety of important uses and applications. They are highly valued synthetic... more Boronic acids have a variety of important uses and applications. They are highly valued synthetic intermediates 1 and also possess significant biological activity. 2 Hydroboration, 3 haloboration, 4 reactions with organometallics, 5 and homologation 6 are important ...
Cheminform, 2010
ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance t... more ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Studies in Inorganic Chemistry, 2006
ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high li... more ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high linear energy transfer of α-particles and recoiling 7Li nuclei. Neither the boron nor the neutrons each alone can cause tissue damage; however, the neutron absorption by the boron provides the high energy to be effective in the biological compartment. For this binary system (BNCT) to be successful, not only high energy neutron beams have to be employed, but also high tumor concentrations of 10B and high tumor: normal tissue ratio must be achieved. BNCT was initially implemented in brain tumors and melanomas; however it seems that it will be gradually expanded to other types of cancer in future. Several boronic entities have been used clinically with limited successful results; however, more entities are being investigated in laboratories with promising potentials. Today, only few clinical trials on BNCT have been conducted around the world, one major reason for its limited use can be attributed to the neutron source, which is a nuclear reactor and its high costs. If the clinical results would justify the costs, BNCT may have the opportunity to become a daily procedure in hospital all over the world. However, the results from the clinical trial of BNCT are not groundbreaking, and that is attributed, as in other cancer therapies, to the lack of sufficient differentiation between tumor and normal cells. The research in the future should be focused on studying and developing new boron entities with such biochemical and physicochemical properties to achieve tumor targeting in vivo, and to bring it to the clinical use.
Acta Crystallographica Section C Crystal Structure Communications
The B atoms in the title compound, C8H16B2Br4N2, bridge between the two monomeric moieties, formi... more The B atoms in the title compound, C8H16B2Br4N2, bridge between the two monomeric moieties, forming a (BN)2 four-membered ring with partial bond orders of the B-N bonds.
ChemInform, 2006
ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance t... more ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
ChemInform, 2006
Organic chemistry Z 0200 α-Boryl Carbonyl Compounds -[31 refs.]. -(ALI, H. A.; DEMBITSKY, V. M.; ... more Organic chemistry Z 0200 α-Boryl Carbonyl Compounds -[31 refs.]. -(ALI, H. A.; DEMBITSKY, V. M.; SREBNIK, M.; Sci. Synth. 6 (2004) 855-865; Dep. Med. Chem., Sch. Pharm., Hebrew Univ., Jerusalem 91120, Israel; Eng.) -Lindner 26-235
Cheminform, 2010
ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance t... more ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Studies in Inorganic Chemistry, 2006
Journal of Coordination Chemistry, 2016
Studies in Inorganic Chemistry, 2006
ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high li... more ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high linear energy transfer of α-particles and recoiling 7Li nuclei. Neither the boron nor the neutrons each alone can cause tissue damage; however, the neutron absorption by the boron provides the high energy to be effective in the biological compartment. For this binary system (BNCT) to be successful, not only high energy neutron beams have to be employed, but also high tumor concentrations of 10B and high tumor: normal tissue ratio must be achieved. BNCT was initially implemented in brain tumors and melanomas; however it seems that it will be gradually expanded to other types of cancer in future. Several boronic entities have been used clinically with limited successful results; however, more entities are being investigated in laboratories with promising potentials. Today, only few clinical trials on BNCT have been conducted around the world, one major reason for its limited use can be attributed to the neutron source, which is a nuclear reactor and its high costs. If the clinical results would justify the costs, BNCT may have the opportunity to become a daily procedure in hospital all over the world. However, the results from the clinical trial of BNCT are not groundbreaking, and that is attributed, as in other cancer therapies, to the lack of sufficient differentiation between tumor and normal cells. The research in the future should be focused on studying and developing new boron entities with such biochemical and physicochemical properties to achieve tumor targeting in vivo, and to bring it to the clinical use.
Studies in Inorganic Chemistry, 2006
This chapter discusses the chemistry of the diboron compounds. Diborane reagents of the general f... more This chapter discusses the chemistry of the diboron compounds. Diborane reagents of the general formula B2(OR)4 have been utilized recently as reagents for a series of transition metal-catalyzed reactions. Synthesis of diboron compounds may involve either reductive coupling reactions of monoboron derivatives to form the boron-boron bond, or reactions of compounds possessing preformed B2 fragments. Two aspects of the boron chemistry of this class of compounds are particularly relevant: (1) First, synthesis and properties of organodiboron derivatives and authentic synthetic failure in this area are of interest in comparison with the rich organic chemistry of monoboron derivatives. (2) Second, the chemistry of subvalent boron compounds and their interactions with organic and organometallic systems can lead to novel reactions that make organoboron derivatives accessible. Bisdiborane derivatives are an important class of compounds in boron chemistry. The addition of diboranes (X2B–BX2) to unsaturated hydrocarbons is an attractive and straightforward method to introduce two boryl units into organic molecules. Diborane itself, B2H4, is stable only when complexed by Lewis base ligands such as amines or phosphines.
ChemInform, 2006
... Similarly, (R)-(-)5,6-dihydro-6-pentyl-2H-pyran-2-one (massoia lactone, 41), isolated from ba... more ... Similarly, (R)-(-)5,6-dihydro-6-pentyl-2H-pyran-2-one (massoia lactone, 41), isolated from bark oil of Criptocarya massoia [42] and jasmine flowers [43] is also found in the defense secretion ... [29] R. Pereda-Miranda, L. Hem~indez, MJ Villavicencio, M. Novelo, P. Ibarra, H. Chai ...
ChemInform, 2007
refs.]. -(DEMBITSKY, V. M.; ABU ALI, H.; SREBNIK, M.; Stud. Inorg. Chem. 22 (2005) 367-389; Dep. ... more refs.]. -(DEMBITSKY, V. M.; ABU ALI, H.; SREBNIK, M.; Stud. Inorg. Chem. 22 (2005) 367-389; Dep. Med. Chem., Sch. Pharm., Hebrew Univ., Jerusalem 91120, Israel; Eng.) -Lindner 26-247
Acta Crystallogr C Cryst Str, 2001
Journal of Organometallic Chemistry, Oct 1, 2009
The dinuclear complex tetra(μ-valproato) dirhodium(II), Rh2(valp)4 (1), and its bis-adducts with ... more The dinuclear complex tetra(μ-valproato) dirhodium(II), Rh2(valp)4 (1), and its bis-adducts with theophylline, Rh2(valp)4(ThH)2 (4), or caffeine, Rh2(valp)4(Caf)2 (5), have been synthesized and characterized by elemental analysis, IR, UV–Vis, magnetic moment, 1H and 13C NMR spectroscopic techniques. Spectral data for the complexes are consistent with a dinuclear structure as found for rhodium (II) tetracarboxylate adducts. Theophylline and caffeine bases in complexes 4 and 5, respectively, are axially coordinated to rhodium (II) atoms through the sterically hindered N(9) site. This is confirmed by X-ray crystal structure analyses of complexes 4 and 5.The dinuclear complex tetra(μ-valproato) dirhodium(II), Rh2(valp)4 (1), and its bis-adducts with theophylline, Rh2(valp)4(ThH)2 (4), or caffeine, Rh2(valp)4(Caf)2 (5), have been synthesized and characterized by various techniques. Within, the syntheses and X-ray structures are reported.
Studies in Inorganic Chemistry, 2006
Organometallics, 2001
Boronic acids have a variety of important uses and applications. They are highly valued synthetic... more Boronic acids have a variety of important uses and applications. They are highly valued synthetic intermediates 1 and also possess significant biological activity. 2 Hydroboration, 3 haloboration, 4 reactions with organometallics, 5 and homologation 6 are important ...
Cheminform, 2010
ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance t... more ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Studies in Inorganic Chemistry, 2006
ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high li... more ABSTRACT BNCT is based on capture reaction between the 10B atom and a neutron to generate high linear energy transfer of α-particles and recoiling 7Li nuclei. Neither the boron nor the neutrons each alone can cause tissue damage; however, the neutron absorption by the boron provides the high energy to be effective in the biological compartment. For this binary system (BNCT) to be successful, not only high energy neutron beams have to be employed, but also high tumor concentrations of 10B and high tumor: normal tissue ratio must be achieved. BNCT was initially implemented in brain tumors and melanomas; however it seems that it will be gradually expanded to other types of cancer in future. Several boronic entities have been used clinically with limited successful results; however, more entities are being investigated in laboratories with promising potentials. Today, only few clinical trials on BNCT have been conducted around the world, one major reason for its limited use can be attributed to the neutron source, which is a nuclear reactor and its high costs. If the clinical results would justify the costs, BNCT may have the opportunity to become a daily procedure in hospital all over the world. However, the results from the clinical trial of BNCT are not groundbreaking, and that is attributed, as in other cancer therapies, to the lack of sufficient differentiation between tumor and normal cells. The research in the future should be focused on studying and developing new boron entities with such biochemical and physicochemical properties to achieve tumor targeting in vivo, and to bring it to the clinical use.
Acta Crystallographica Section C Crystal Structure Communications
The B atoms in the title compound, C8H16B2Br4N2, bridge between the two monomeric moieties, formi... more The B atoms in the title compound, C8H16B2Br4N2, bridge between the two monomeric moieties, forming a (BN)2 four-membered ring with partial bond orders of the B-N bonds.
ChemInform, 2006
ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance t... more ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
ChemInform, 2006
Organic chemistry Z 0200 α-Boryl Carbonyl Compounds -[31 refs.]. -(ALI, H. A.; DEMBITSKY, V. M.; ... more Organic chemistry Z 0200 α-Boryl Carbonyl Compounds -[31 refs.]. -(ALI, H. A.; DEMBITSKY, V. M.; SREBNIK, M.; Sci. Synth. 6 (2004) 855-865; Dep. Med. Chem., Sch. Pharm., Hebrew Univ., Jerusalem 91120, Israel; Eng.) -Lindner 26-235